Exelixis, Inc. (EXEL) Presents at The Citizens Life Sciences Conference 2026 Transcript

Core Insights - The company Exelixis experienced significant growth in 2025, driven by pivotal data from its zanza program and strong performance in its commercial and development organizations [1] - CABOMETYX, a key product, has received approval for seven different indications, contributing to the company's growth [1] Business Performance - The primary growth driver for Exelixis is the renal cell carcinoma (RCC) business, along with a recent launch in neuroendocrine tumors [2]